Loading...

Market-leading

prenatal screening tes

Learn More scroll down

What is Panorama®?

Panorama is a market-leading noninvasive prenatal screening test (NIPT) that reveals your baby’s risk for genetic disorders as early as nine weeks. Panorama analyzes baby's (placental) DNA through a simple blood draw from the mother’s arm.

Personalized results

Panorama offers patients a personalized risk score, which indicates whether your baby is at high or low risk for genetic disease. Your report may state the following:
Team Member

Low Risk

A low risk result indicates that it is very unlikely that your baby is affected by one of the conditions on the Panorama panel.

Low Risk

Team Member

High Risk

A high risk result does not mean the baby has a chromosomal abnormality; rather, it indicates a very high probability that your baby may have that condition. Your healthcare provider may recommend that you speak with a genetic counselor and/ or maternal fetal medicine specialist. You may be offered invasive diagnostic testing such as amniocentesis or CVS. No irreversible pregnancy decisions should ever be made based on a Panorama result alone.

High Risk

Team Member

No Result

In a small percentage of cases, Panorama may not be able to obtain sufficient information from your blood sample to determine an accurate result. If this occurs, a second blood sample may be requested.

No Result

What It Screens

A full panel of options

Panorama screens for the most common genetic conditions and the baby’s gender (optional). Some conditions, such as Down syndrome, are caused by extra copies of a specific chromosome. Others, such as microdeletions, occur when a chromosome is missing a small piece of genetic information. Microdeletions affect women equally, regardless of age. Panorama is a screening test. Genetic counseling and diagnostic testing are recommended to confirm positive findings.

Trisomy

A trisomy is a genetic condition caused by extra copies of a chromosome. Down syndrome, one of the most well-known genetic conditions, is caused by an extra copy of chromosome 21. Generally, the larger the extra chromosome is in size, the more severe problems it will cause. For instance, chromosome 21 is the second smallest autosomal chromosome, and babies with Down syndrome often lead healthy and productive lives. However, babies with Trisomy 13, or Patau syndrome, will typically pass away within the first few weeks of life.

Down syndrome

Trisomy 21

Babies with Down syndrome have three copies of chromosome 21 and have intellectual disabilities that range from mild to severe. Children with Down syndrome will need extra medical care depending on the child’s specific health problems. Early intervention has allowed many individuals with Down syndrome to lead healthy and productive lives. The presence of medical conditions, like heart defects, can affect the lifespan in these children and adults; however, most individuals with Down syndrome will live into their 60s. Miscarriage occurs in about 30% of pregnancies with Down syndrome while overall about 1 in 700 babies are born with Down syndrome.

Edwards syndrome

Trisomy 18

Babies with trisomy 18 have three copies of chromosome 18 and have severe intellectual disabilities and birth defects typically involving the heart, brain, and kidneys. Babies with trisomy 18 can also have visible birth defects such as an opening in the lip (cleft lip) with or without an opening in the roof of the mouth (cleft palate), small head, clubbed feet, underdeveloped fingers and toes, and a small jaw. Unfortunately, most pregnancies with trisomy 18 will miscarry. If born alive, most affected babies with trisomy 18 will pass away within the first few weeks of life. About 10 percent survive to their first birthday. Trisomy 18 occurs in approximately 1 in 3,000 live births.

Patau syndrome

Trisomy 13

Babies with trisomy 13 have three copies of chromosome 13 and have severe intellectual disabilities. They often have birth defect involving the heart, brain and kidneys. Visible abnormalities include extra fingers and or toes or an opening in the lip, with or without an opening in the palate. Given the severe disabilities, most pregnancies affected by trisomy 13 will miscarry.If born alive, most affected babies with trisomy 13 will pass away within the first few weeks of life. About 10 percent survive to their first birthday. Trisomy 13 occurs in approximately 1 in 5,000 live births.

The Panorama process

01

Step

Physician orders Panorama.

02

Step

Blood sample collected.

03

Step

Sample shipped to Natera and analyzed.

04

Step

Results sent to physician in about 5 - 7 calendar days.

COMMON QUESTIONS

The cost of Panorama varies with the prenatal screening panel selected, and your specific insurance coverage. Estimate your out-of-pocket costs using our Test Cost Estimator. For more information about your financial responsibility, please call Natera at 877-869-3052. You may be eligible for a payment plan and/or assistance for financial hardship*.
Insurance coverage for Panorama is contingent on your health insurance plan and coverage benefits. For a link to all the insurance plans Panorama has a contract with as an in-network laboratory
Yes, Natera offers payments plans starting as low as $25/month*. Please call Natera at 877-869-3052 to check eligibility and payment plan options.
An EOB is NOT a bill. EOB stands for Explanation of Benefits and describes how your insurance plan pays for your test and if there is any additional amount that you may be responsible for. The EOB typically precedes your bill. If you have any questions about your EOB, please call a Natera billing specialist at 877-869-3052.
If you are interested in obtaining the Panorama test, you can start a conversation about non-invasive prenatal testing with your doctor on your first prenatal visit.
Panorama only requires a simple blood draw from the mom.
Panorama is able to determine the likelihood that the pregnancy could be affected with chromosome abnormalities including Down syndrome (trisomy 21), trisomy 18, trisomy 13, monosomy X and triploidy. Your doctor may also recommend additional chromosomal conditions (microdeletions) be screened for using Panorama. Microdeletion conditions on Panorama’s extended panel include 22q11.2 deletion syndrome, 1p36 deletion, Cri-du-chat syndrome, Prader-Willi syndrome and Angelman syndrome. While it is not the sole purpose of the test, the sex of the baby can also be screened for using Panorama.
You can ask your doctor to learn more about Panorama prenatal screen. Board-certified genetic counselors are also available to answer questions about Panorama prenatal screen.
As early as nine weeks into your pregnancy, a simple blood draw can tell you if your baby is at higher risk for having Down syndrome and other common genetic conditions, as well as the sex of your baby. Non-invasive and highly accurate, Panorama identifies more than 99% of pregnancies affected with Down syndrome and has the lowest reported false positive rate of any prenatal screening test for the commonly screened chromosomal abnormalities: trisomy 21, trisomy 18, and trisomy 13.
The Panorama prenatal screen is designed for women of any age and ethnicity who are at least 9 weeks pregnant. It cannot currently be used by women carrying three or more babies (triplets and above), women who have used an egg donor or surrogate carrying more than one baby (twins or triplets), or those who have received a bone marrow transplant.
Panorama can be performed as early as 9 weeks into the pregnancy.
You will receive your results from your doctor’s office. They may tell you the results over the phone or ask you to come into their office.
When you get your Panorama results, your report may state the following: Low Risk: A Low Risk result indicates that it is unlikely that your baby is affected by one of the conditions on the Panorama panel. High Risk: A High Risk result does not mean the baby is affected; rather, it indicates a higher than average chance that the baby has a chromosome abnormality. Your healthcare provider may recommend that you speak with a genetic counselor and or maternal fetal medicine specialist. You may be offered invasive diagnostic testing such as amniocentesis or CVS. No irreversible pregnancy decisions should ever be made based on a Panorama result alone. No Result: In a small percentage of cases, Panorama may not be able to obtain sufficient information from your blood sample to determine an accurate result. If this occurs, a second blood sample may be requested.
Typically, you will receive your Panorama screen results from the healthcare provider who ordered the test. If you have specific question about your results, we encourage you to schedule a complementary genetic information session with a Natera board certified genetic counselor.

Clinical Info

NIPT: any woman, any age

Since 2012, more than 68,613 patients younger than 35 years of age have been evaluated in eight studies. 28 health plans covering more than 75.1 million lives have updated their medical policies to include NIPTs as medically necessary for fetal aneuploidies in all singleton pregnancies. Panorama is validated in both high- and average-risk cohorts and demonstrates similar positive predictive values (PPV)

Panorama: the power of SNPs

Panorama is the only commercially available NIPT that specifically analyzes single nucleotide polymorphisms (SNPs) to determine chromosome copy number. Validated at fetal fraction as low as 2.8%, this approach sequences cell-free DNA from maternal plasma to infer the fetal genotype. Panorama targets 13,392 SNPs covering chromosomes 21, 18, 13, X, and Y; additional sets of SNPs are targeted for identification of microdeletions.

The importance of fetal fraction

Joint Statement of the American Congress of Obstetrics and Gynecology and the Society for Maternal-Fetal Medicine: “Fetal fraction…is essential for accurate results.” According to the joint statement, failure to measure fetal fraction can increase the chance of a false-negative result. "The ability to differentiate maternal and fetal DNA is reduced at lower fetal fractions." "Detection of subchromosomal microdeletions improves significantly at higher fetal fractions."